Nov. 27, 2020
TEC Project Services Corporation (TPS, President and CEO Takayoshi Imanishi), a domestic subsidiary of Toyo Engineering Corporation was awarded a middle molecular drug substances (oligonucleotide drugs and peptide drugs) manufacturing plant at Tokai plant from Ajinomoto Co., Inc. TPS participates from the basic planning stage of this project and executes lump sum of Engineering, Procurement, Construction, and Commissioning of the plant.
TPS concentrates on the pharmaceutical field as one of its core sectors actively engaged in from the planning stage to the construction, especially on the middle molecular and biopharmaceutical manufacturing plants which are expected to grow up these days.
This project will build one of the largest plants ever in Japan to manufacture active pharmaceutical ingredients for oligonucleotide drugs and peptide drugs, which are regarded as next-generation pharmaceutical products. With this new plant, Ajinomoto will expand the business of Ajinomoto Bio-Pharma Services, which is responsible for development and manufacturing of biopharmaceuticals by realizing expansion of the production capacity of oligonucleotide and peptide drugs by their original synthesis technology "AJIPHASE®".
TPS will expand its business by promoting initiatives in the next-generation pharmaceutical fields, including oligonucleotide drugs, peptide drugs, and biopharmaceuticals.
TPS concentrates on the pharmaceutical field as one of its core sectors actively engaged in from the planning stage to the construction, especially on the middle molecular and biopharmaceutical manufacturing plants which are expected to grow up these days.
This project will build one of the largest plants ever in Japan to manufacture active pharmaceutical ingredients for oligonucleotide drugs and peptide drugs, which are regarded as next-generation pharmaceutical products. With this new plant, Ajinomoto will expand the business of Ajinomoto Bio-Pharma Services, which is responsible for development and manufacturing of biopharmaceuticals by realizing expansion of the production capacity of oligonucleotide and peptide drugs by their original synthesis technology "AJIPHASE®".
TPS will expand its business by promoting initiatives in the next-generation pharmaceutical fields, including oligonucleotide drugs, peptide drugs, and biopharmaceuticals.
Contract Summary
| Client | Ajinomoto Co., Inc. |
|---|---|
| Contractor | TEC Project Services Corporation |
| Site | Yokkaichi-shi, Mie, Japan |
| Facility | Middle molecular drug substances manufacturing plant |
| Scope | Turnkey contract for engineering, procurement, and construction |
| Completion | March 2022 (scheduled) |